As part of the delegation led by Business France, Hemerion is participating in the new edition of BIO held in Boston: an opportunity to forge new scientific partnerships and accelerate the development of its therapeutic innovations, particularly in the treatment of brain cancer.
Hemerion will participate in Bio Convention 2025, held in Boston from June 16 to 19. Bio is the major international business convention dedicated to biotechnologies. It brings together over 20,000 participants and 1,500 exhibitors.
Hemerion has been invited to join the delegation of biotech / healthtech companies led by Business France, which includes more than 120 innovative companies.
For the Hemerion team, this is an opportunity to meet future partners and funders for its upcoming clinical trial and to prepare for the market launch of the first therapeutic indication of its combined Pentalafen® / Heliance® technology in the treatment of glioblastoma, the most severe form of brain cancer. This launch is planned for around 2030 in the American and European markets.
Hemerion also aims to secure new preclinical and clinical research partnerships in the treatment of solid tumors and to explore the possible synergies of its technology with immuno-oncology solutions.